Skip to content

Vor Biopharma VOR Earnings yield

Earnings yield at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
3.6%-1.9pp
Amgen logo
AmgenAMGN
4.1%+0.6pp
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
3.8%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-8.1%+1.2pp
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
-10.6%-3.9pp
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-25.7%-6.8pp

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$809M+2,594%
Enterprise value$642.06M+5,866%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Calculated from Vor Biopharma’s reported figures.

Based on trailing twelve months.

The official record: Vor Biopharma’s 10-Q, filed November 13, 2025, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's earnings yield?
Vor Biopharma (VOR) reported earnings yield of -733.6% in Q3 2025.
How has Vor Biopharma's earnings yield changed year-over-year?
Vor Biopharma's earnings yield decreased by 211.8% year-over-year, from -235.2% to -733.6%.
What is the long-term trend for Vor Biopharma's earnings yield?
Over 3 years (2021 to 2024), Vor Biopharma's earnings yield has grown at a 74.6% compound annual growth rate (CAGR), from -15.9% to -84.6%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.